Zymeworks Inc. logo

Zymeworks Inc.

NYSE:ZYME

Overview | Financials
Company Name Zymeworks Inc.
Symbol ZYME
Currency USD
Price 14.14
Market Cap 973,927,850
Dividend Yield 0%
52-week-range 7.97 - 17.7
Industry Biotechnology
Sector Healthcare
CEO Mr. Kenneth H. Galbraith C.A.
Website https://www.zymeworks.com

An error occurred while fetching data.

About Zymeworks Inc.

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and

Related Stocks

Rite Aid Corporation logo

Rite Aid Corporation

RAD

0.648 USD

ATI Physical Therapy, Inc. logo

ATI Physical Therapy, Inc.

ATIP

2.43 USD

Vicarious Surgical Inc. logo

Vicarious Surgical Inc.

RBOT

12 USD

Owlet, Inc. logo

Owlet, Inc.

OWLT

4.64 USD

Financials

Numbers are in millions USD

Numbers are in millions USD